Advice

in the absence of a submission from the holder of the marketing authorisation:

lenalidomide (Revlimid®) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice354KB (PDF)

Download

Medicine details

Medicine name:
lenalidomide (Revlimid)
SMC ID:
SMC2125
Indication:
As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
08 October 2018